Lantheus Holdings Inc
Research Lantheus Holdings Inc (LNTH) on Bullrun: valuation model: 1.0% undervalued, market cap USD 6.58B, P/E 24.4. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLNTH
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Valuation signal1.0% undervalued
- Market capUSD 6.58B
- P/E24.4
- Financial periodQ2 2026
- RevenueUSD 388.18M
- Net incomeUSD 75.03M
- Free cash flowUSD 89.87M
- Gross margin62.3%
Valuation Snapshot
Bullrun's latest valuation model marks Lantheus Holdings Inc as 1.0% undervalued; latest market cap is USD 6.58B; P/E is 24.4.
Peer valuation comparison
Latest P/E is 24.38x versus a Healthcare sector median of 24.46x.
Latest P/E is 24.38x versus a United States median of 24.87x.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 1.54B | USD 233.56M | USD 348.64M | 61.1% | 3.41 | USD 359.12M | USD 738.00K | USD 1.09B |
| FY2024 | USD 1.53B | USD 312.44M | USD 493.13M | 64.4% | 4.36 | USD 912.81M | USD 974.00K | USD 1.09B |
| FY2023 | USD 1.30B | USD 326.66M | USD 259.92M | 54.7% | 4.65 | USD 713.66M | USD 823.00K | USD 815.89M |
| FY2022 | USD 935.06M | USD 28.07M | USD 21.78M | 62.2% | 0.4 | USD 415.65M | USD 558.07M | USD 447.15M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 6.58B | 24.4 | n/a | n/a |
| 2025 | 2025-12-31 | USD 4.30B | 19.7 | n/a | n/a |
| 2024 | 2024-12-31 | USD 6.12B | 20.5 | n/a | n/a |
| 2023 | 2023-12-29 | USD 4.25B | 43.4 | n/a | n/a |
| 2022 | 2022-12-30 | USD 3.51B | 34.2 | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.96B | n/a | n/a | n/a |
About Lantheus Holdings Inc
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function;
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Lantheus Holdings Inc overvalued or undervalued?
Bullrun's valuation model currently marks Lantheus Holdings Inc as 1.0% undervalued.
What is Lantheus Holdings Inc's market cap?
Lantheus Holdings Inc's market capitalization is USD 6.58B.
What is Lantheus Holdings Inc's P/E ratio?
Lantheus Holdings Inc's price-to-earnings (P/E) ratio is 24.4.
What does Lantheus Holdings Inc do?
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.